GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: MCLA-158 | MCLA158
Compound class:
Antibody
Comment: Petosemtamab (MCLA-158) is a bispecific epidermal growth factor receptor (EGFR)/leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) IgG1 monoclonal antibody that was designed for anti-tumour potential [2-3]. In sensitive cancer cells petosemtamab promotes internalisation and degradation of EGFR, inhibits EGFR signalling and engages an anti-tumour immune response via LGR5. It has enhanced ADCC activity against EGFR-driven head and neck squamous cell carcinoma (HNSCC) LGR5-expressing cancer stem cells [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
Classification  |
|
| Compound class | Antibody |
| International Nonproprietary Names |
|
| INN number | INN |
| 11136 | petosemtamab |
| Synonyms |
| MCLA-158 | MCLA158 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 965 |
| Other databases | |
| Search PubMed clinical trials | petosemtamab |
| Search PubMed titles | petosemtamab |
| Search PubMed titles/abstracts | petosemtamab |
